Literature DB >> 10702277

2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases.

H S Andersen1, L F Iversen, C B Jeppesen, S Branner, K Norris, H B Rasmussen, K B Møller, N P Møller.   

Abstract

Protein-tyrosine phosphatases (PTPs) are critically involved in regulation of signal transduction processes. Members of this class of enzymes are considered attractive therapeutic targets in several disease states, e.g. diabetes, cancer, and inflammation. However, most reported PTP inhibitors have been phosphorus-containing compounds, tight binding inhibitors, and/or inhibitors that covalently modify the enzymes. We therefore embarked on identifying a general, reversible, competitive PTP inhibitor that could be used as a common scaffold for lead optimization for specific PTPs. We here report the identification of 2-(oxalylamino)-benzoic acid (OBA) as a classical competitive inhibitor of several PTPs. X-ray crystallography of PTP1B complexed with OBA and related non-phosphate low molecular weight derivatives reveals that the binding mode of these molecules to a large extent mimics that of the natural substrate including hydrogen bonding to the PTP signature motif. In addition, binding of OBA to the active site of PTP1B creates a unique arrangement involving Asp(181), Lys(120), and Tyr(46). PTP inhibitors are essential tools in elucidating the biological function of specific PTPs and they may eventually be developed into selective drug candidates. The unique enzyme kinetic features and the low molecular weight of OBA makes it an ideal starting point for further optimization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702277     DOI: 10.1074/jbc.275.10.7101

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  The structure of apo protein-tyrosine phosphatase 1B C215S mutant: more than just an S --> O change.

Authors:  G Scapin; S Patel; V Patel; B Kennedy; E Asante-Appiah
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

Review 2.  Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases.

Authors:  X Espanel; S Wälchli; R P Gobert; M El Alama; M L Curchod; N Gullu-Isler; R Hooft van Huijsduijnen
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

3.  Structure-based prediction of free energy changes of binding of PTP1B inhibitors.

Authors:  Jing Wang; Shek Ling Chan; Kal Ramnarayan
Journal:  J Comput Aided Mol Des       Date:  2003-08       Impact factor: 3.686

Review 4.  Generation of inhibitor-sensitive protein tyrosine phosphatases via active-site mutations.

Authors:  Anthony C Bishop; Xin-Yu Zhang; Anna Mari Lone
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

Review 5.  Phosphotyrosine isosteres: past, present and future.

Authors:  Robert A Cerulli; Joshua A Kritzer
Journal:  Org Biomol Chem       Date:  2019-11-28       Impact factor: 3.876

6.  A two stage click-based library of protein tyrosine phosphatase inhibitors.

Authors:  Jian Xie; Christopher T Seto
Journal:  Bioorg Med Chem       Date:  2006-10-12       Impact factor: 3.641

7.  Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases.

Authors:  Lok Hang Mak; Jessica Knott; Katherine A Scott; Claire Scott; Gillian F Whyte; Yu Ye; David J Mann; Oscar Ces; James Stivers; Rudiger Woscholski
Journal:  Bioorg Med Chem       Date:  2012-05-24       Impact factor: 3.641

8.  Allele-specific inhibition of divergent protein tyrosine phosphatases with a single small molecule.

Authors:  Xin-Yu Zhang; Vincent L Chen; Mari S Rosen; Elizabeth R Blair; Anna Mari Lone; Anthony C Bishop
Journal:  Bioorg Med Chem       Date:  2008-07-24       Impact factor: 3.641

9.  Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis.

Authors:  Anja K Pedersen; Xiao-Ling Guo; Karin B Møller; Günther H Peters; Henrik S Andersen; Jette S Kastrup; Steen B Mortensen; Lars F Iversen; Zhong-Yin Zhang; Niels Peter H Møller
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

10.  A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2beta).

Authors:  Paul G Drake; Günther H Peters; Henrik Sune Andersen; Wiljan Hendriks; Niels Peter H Møller
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.